HansBiomed Corporation

₩15,290As of Sun 8 Nov 2026, 12:00 UTC
KOSDAQ:042520Healthcare
Country South Korea
PE (Fwd) •••
TSR 10Y CAGR 0.47%
Div yield —
ROE (29.22%)
Biological Products, Except Diagnostic Substances
Beta (5Y) 2.00
PE TTM —
TSR TTM (43.05%)
Mkt cap ₩218.1B
ROIC (18.47%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩19,733
29.06%
460.93%
Hold 7|11|9|1|2
1Q26
2Q26
3Q26
4Q26
Earnings per share₩
302.98
330.61
360.62
349.20
8.20%
12.72%
24.04%
25.09%
Revenue₩B
21.44
21.68
21.44
22.16
2.91%
5.72%
6.14%
7.29%
Peers (US$160.8M)
Cap (US$)
PE
145.8M
—
Capital
TTM
5Y
10Y
Leveragex
0.861
0.203
0.191
EBIT/Intx
0.194
0.168
0.133
Own earn%
110.12
12.50
8.67
Sh yield%
34.80
28.68
28.47
Owners
Insiders/Inst%
1.84
61.63
Short interest%
0.52
SBC / revenue%
2.38
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
1
Op margin range%
0–5
$1 testx
—
Incr. ROIC%
9